TrialsgramBetaRCTs are beautiful
AHA Scientific Sessions 2026Präsentiert So., 8. Nov. · 16:00 GMT-6LBS.04 Late-breaking Science: Innovations to Optimize Arrhythmia CareAlle Studien (Late-Breaking Science) →

SUPERIOR

2026

Sacubitril/Valsartan for Preventing Recurrence of Atrial Fibrillation After Catheter Ablation in Patients With Hypertension: A Multicenter, Randomized Controlled Trial (SUPERIOR)

In patients with atrial fibrillation and hypertension undergoing catheter ablation, sacubitril/valsartan was associated with a lower rate of documented atrial arrhythmia recurrence at 12 months compared with valsartan.

Ergebnis

Recurrence of atrial arrhythmia after ablation (definition not public)
Absolute Differenz
10,3 Punkte

Die absolute Differenz ist aus den Ereignisraten abgeleitet.

Außerdem berichtet: Clinic systolic blood pressure fell by about 10 mm Hg in both groups, with no significant difference in the reduction in 24-hour ambulatory blood pressure.

Originalpublikation
Unterthema
Upstream therapy
Design
Multicentre randomised controlled trial (per the programme) of sacubitril/valsartan for preventing AF recurrence after catheter ablation in hypertension
Eingeschlossen
320 Patienten
Quelle
Zhang W. Presented at AHA Scientific Sessions 2026, 8 November. American Heart Association newsroom. Not yet published.

Diskussion & Kritik

This randomised trial in 320 patients reports a lower rate of documented atrial arrhythmia recurrence with sacubitril/valsartan than with valsartan alone over 12 months after ablation. The release gives no hazard ratio, confidence interval, P value or safety data, so neither the precision nor the statistical significance of the difference can be judged. The trial was open label, although recurrences were adjudicated by a blinded team, and intermittent rhythm monitoring may have missed brief or asymptomatic episodes. Follow-up was limited to 12 months at three hospitals in China, and the findings come from an abstract that has not been peer reviewed.